Find Acalabrutinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

96RELATED EXCIPIENT COMPANIES

145EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1420477-60-6, Acp-196, Calquence, Acalabrutinib (acp-196), Acalabrutinib [inn], I42748elqw
Molecular Formula
C26H23N7O2
Molecular Weight
465.5  g/mol
InChI Key
WDENQIQQYWYTPO-IBGZPJMESA-N
FDA UNII
I42748ELQW

Acalabrutinib
Acalabrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Acalabrutinib is a Kinase Inhibitor. The mechanism of action of acalabrutinib is as a Tyrosine Kinase Inhibitor.
1 2D Structure

Acalabrutinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
2.1.2 InChI
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
2.1.3 InChI Key
WDENQIQQYWYTPO-IBGZPJMESA-N
2.1.4 Canonical SMILES
CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
2.1.5 Isomeric SMILES
CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
2.2 Other Identifiers
2.2.1 UNII
I42748ELQW
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Acp-196

2. Calquence

2.3.2 Depositor-Supplied Synonyms

1. 1420477-60-6

2. Acp-196

3. Calquence

4. Acalabrutinib (acp-196)

5. Acalabrutinib [inn]

6. I42748elqw

7. 4-[8-amino-3-[(2s)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-n-pyridin-2-ylbenzamide

8. Benzamide, 4-(8-amino-3-((2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-n-2-pyridinyl-

9. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

10. Acalabrutinib(acp196)

11. Acalabrutinib [usan:inn]

12. Acalabrutinibum

13. Unii-i42748elqw

14. Calquence (tn)

15. Benzamide, 4-[8-amino-3-[(2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-n-2-pyridinyl-

16. Acp-196;acalabrutinib

17. Acalabrutinib [mi]

18. Acalabrutinib [jan]

19. Acalabrutinib [usan]

20. Acalabrutinib [who-dd]

21. Gtpl8912

22. Acalabrutinib (jan/usan/inn)

23. Chembl3707348

24. Schembl14637368

25. Acp 196

26. Amy5290

27. Ex-a881

28. Chebi:167707

29. Dtxsid401026209

30. Acalabrutinib [orange Book]

31. Bdbm50175583

32. Mfcd29472294

33. Nsc791164

34. Nsc800976

35. S8116

36. Zinc208774715

37. Ccg-269407

38. Cs-5356

39. Db11703

40. Ds-3326

41. Nsc-791164

42. Nsc-800976

43. Ncgc00479074-01

44. Hy-17600

45. Example 6 [us20140155385 A1]

46. D10893

47. A857446

48. J-690166

49. Q23668732

50. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide;acalabrutinib

51. (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

52. 4-[8-amino-3-[(2s)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-n-2-pyridinyl-benzamide

53. 4-[8-amino-3-[(2s)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-n-(2-pyridyl)benzamide

54. 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-n-(pyridin-2-yl)benzamide

2.4 Create Date
2013-03-21
3 Chemical and Physical Properties
Molecular Weight 465.5 g/mol
Molecular Formula C26H23N7O2
XLogP33
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass465.19132300 g/mol
Monoisotopic Mass465.19132300 g/mol
Topological Polar Surface Area119 Ų
Heavy Atom Count35
Formal Charge0
Complexity845
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameCALQUENCE
Active IngredientACALABRUTINIB
CompanyASTRAZENECA (Application Number: N210259. Patents: 9290504, 9758524, 9796721)

4.2 Drug Indication

Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.


FDA Label


Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Acalabrutinib is a Bruton Tyrosine Kinase inhibitor that prevents the proliferation, trafficking, chemotaxis, and adhesion of B cells. It is taken every 12 hours and can cause other effects such as atrial fibrillation, other malignancies, cytopenia, hemorrhage, and infection.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ACALABRUTINIB
5.3.2 FDA UNII
I42748ELQW
5.3.3 Pharmacological Classes
Tyrosine Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
5.4 ATC Code

L01XE51


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EL - Bruton's tyrosine kinase (btk) inhibitors

L01EL02 - Acalabrutinib


5.5 Absorption, Distribution and Excretion

Absorption

The geometric mean absolute bioavailability of acalabrutinib is 25% with a median time to peak plasma concentrations (Tmax) of 0.75 hours.


Route of Elimination

After administration of a single 100 mg radiolabelled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine. An irradiated dose of acalabrutinib was 34.7% recovered as the metabolite ACP-5862; 8.6% was recovered as unchanged acalabrutinub; 10.8 was recovered as a mixture of the M7, M8, M9, M10, and M11 metabolites; 5.9% was the M25 metabolite; 2.5% was recovered as the M3 metabolite.


Volume of Distribution

The mean steady-state volume of distribution is approximately 34 L.


Clearance

Acalabrutinib's mean apparent oral clearance (CL/F) is observed to be 159 L/hr with similar PK between patients and healthy subjects, based on population PK analysis.


5.6 Metabolism/Metabolites

Acalabrutinib is mainly metabolized by CYP3A enzymes. ACP-5862 is identified to be the major active metabolite in plasma with a geometric mean exposure (AUC) that is about 2-3 times greater than the exposure of acalabrutinib. ACP-5862 is about 50% less potent than acalabrutinib in regards to the inhibition of BTK.


5.7 Biological Half-Life

After administering a single oral dose of 100 mg acalabrutinib, the median terminal elimination half-life of the drug was found to be 0.9 (with a range of 0.6 to 2.8) hours. The half-life of the active metabolite, ACP-5862, is about 6.9 hours.


5.8 Mechanism of Action

Mantle Cell Lymphoma (MCL) is a rare yet aggressive type of B-cell non-Hodgkin lymphoma (NHL) with poor prognosis. Subsequently, relapse is common in MCL patients and ultimately represents disease progression. Lymphoma occurs when immune system lymphocytes grow and multiply uncontrollably. Such cancerous lymphocytes may travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, and other organs where they can multiply and form a mass(es) called a tumor. One of the main kinds of lymphocytes that can develop into cancerous lymphomas are the body's own B-lymphocytes (B-cells). Bruton Tyrosine Kinase (BTK) is a signalling molecule of the B-cell antigen receptor and cytokine receptor pathways. Such BTK signaling causes the activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib is a small molecule inhibitor of BTK. Both acalabrutinib and its active metabolite, ACP-5862, act to form a covalent bond with a cysteine residue (Cys481) in the BTK active site, leading to inhibition of BTK enzymatic activity. As a result, acalabrutinib inhibits BTK-mediated activation of downstream signaling proteins CD86 and CD69, which ultimately inhibits malignant B-cell proliferation and survival Whereas ibrutinib is typically recognized as the first-in-class BTK inhibitor, acalabrutinib is considered a second generation BTK inhibitor primarily because it demonstrates highter selectivity and inhibition of the targeted activity of BTK while having a much greater IC50 or otherwise virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In effect, acalabrutinib was rationally designed to be more potent and selective than ibrutinib, all the while demonstrating fewer adverse effects - in theory - because of the drug's minimized off target effects.


API SUPPLIERS

read-more
read-more

01

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

02

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Egis Pharmaceuticals

03

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Aarti Industries Company Banner

04

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

08

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35796

Submission : 2021-04-20

Status : Active

Type : II

Aarti Industries Company Banner

02

AACR Annual meeting
Not Confirmed

03

Cipla Ltd

India

USDMF

arrow
AACR Annual meeting
Not Confirmed

03

Cipla Ltd

India
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-10-30

Pay. Date : 2023-09-22

DMF Number : 38325

Submission : 2023-07-14

Status : Active

Type : II

blank

04

Cipla Ltd

India

USDMF

arrow
AACR Annual meeting
Not Confirmed

04

Cipla Ltd

India
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-06-03

Pay. Date : 2021-04-16

DMF Number : 35762

Submission : 2021-05-03

Status : Active

Type : II

blank

05

AACR Annual meeting
Not Confirmed

05

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-06-25

Pay. Date : 2024-06-07

DMF Number : 39468

Submission : 2024-03-28

Status : Active

Type : II

blank

06

AACR Annual meeting
Not Confirmed

07

AACR Annual meeting
Not Confirmed

07

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-07-09

Pay. Date : 2021-05-25

DMF Number : 35558

Submission : 2021-02-01

Status : Active

Type : II

blank

08

Natco Pharma Ltd

India

USDMF

arrow
AACR Annual meeting
Not Confirmed

08

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-10-13

Pay. Date : 2021-09-20

DMF Number : 36263

Submission : 2021-09-15

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib IH

Date of Issue : 2022-09-02

Valid Till : 2025-05-05

Written Confirmation Number : WC-0349

Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

Registrant Name : AstraZeneca Korea Ltd.

Registration Date : 2021-02-05

Registration Number : Su248-15-ND

Manufacturer Name : Dottikon Exclusive Synthesis...

Manufacturer Address : Hembrunnstrasse 17, 5605 Dottikon, Switzerland

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

Registrant Name : AstraZeneca Korea Ltd.

Registration Date : 2023-02-25

Registration Number : Su248-19-ND

Manufacturer Name : Dottikon Exclusive Synthesis...

Manufacturer Address : Hembrunnstrasse 17, 5605 Dottikon, Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

AstraZeneca UK Limited

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

AstraZeneca UK Limited

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB

NDC Package Code : 60440-0512

Start Marketing Date : 2017-11-03

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (20kg/20kg)

Marketing Category : BULK INGREDIENT

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB MALEATE

NDC Package Code : 54864-601

Start Marketing Date : 2022-04-21

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB

NDC Package Code : 54893-0108

Start Marketing Date : 2021-01-29

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB MALEATE MONOHYDRATE

NDC Package Code : 54893-0507

Start Marketing Date : 2024-03-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB DIHYDRATE

NDC Package Code : 63850-8113

Start Marketing Date : 2023-11-25

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

MAEDA INC

Country
AACR Annual meeting
Not Confirmed
arrow

MAEDA INC

Country
arrow
AACR Annual meeting
Not Confirmed

ACALABRUTINIB

NDC Package Code : 86184-001

Start Marketing Date : 2023-08-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Acalabrutinib

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Acalabrutinib

About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.
Egis Pharmaceuticals

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

05

Cipla

India
AACR Annual meeting
Not Confirmed
arrow

Cipla

India
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Since inception in 1935, caring has been at the core of everything we do at Cipla. For patients, caring is a promise that we will do whatever it takes to ensure they have continued access to the highest quality medicines at affordable prices; whether a disease affects millions or just a few hundreds.
blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...

Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, catering to both export and import markets. The company consists of two primary business departments: the Professional Sourcing/Product Team and the Quality Team. Backed by experienced partners, Longshine has evolved into a trustworthy supplier of high-quality products and received ISO9001:2008 certification in 2017.
blank

07

Hetero Drugs

India
AACR Annual meeting
Not Confirmed
arrow

Hetero Drugs

India
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

08

Natco Pharma

India
AACR Annual meeting
Not Confirmed
arrow

Natco Pharma

India
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...

NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, NATCO today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.NATCO family currently consists of more than 2500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. NATCO is well recognized for its innovation in Pharmaceutical R&D.
blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

About the Company : Founded in 2003, Zhejiang Tianyu Pharmaceutical Co., Ltd. is a joint-stock pharmaceutical company specializing in the research, development and manufacture of APIs and advanced pha...

Founded in 2003, Zhejiang Tianyu Pharmaceutical Co., Ltd. is a joint-stock pharmaceutical company specializing in the research, development and manufacture of APIs and advanced pharmaceutical intermediates. The company has a registered capital of 120 million yuan and covers an area of ​​700 mu. The factory has more than 2,600 employees.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"ACALABRUTINIB","year":"2021","qtr":"Q1","strtotime":1616178600,"product":"ACALABRUTINIB-(SL NO:1597 OF APPENDIX 3B -MEIS)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"21332.5","totalValueFC":"25334.8","currency":"USD","unitRateINR":1537006.2,"date":"20-Mar-2021","totalValueINR":"1844407.44","totalValueInUsd":"25334.8","indian_port":"HYDERABAD AIR","hs_no":"29400000","bill_no":"9517261","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684953000,"product":"MSN PHARMACEUTICAL PRODUCT NAME ACALABRUTINIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF GULF AGENCY","customerCountry":"UNITED ARAB EMIRATES","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"24750","totalValueFC":"97625","currency":"USD","unitRateINR":2008250,"date":"25-May-2023","totalValueINR":"8033000","totalValueInUsd":"97625","indian_port":"HYDERABAD AIR","hs_no":"29400000","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"MSN PHARMA -ACALABRUTINIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"35000","totalValueFC":"51717.7","currency":"USD","unitRateINR":2833999.8959999997,"date":"30-Jun-2023","totalValueINR":"4250999.844","totalValueInUsd":"51717.7","indian_port":"HYDERABAD AIR","hs_no":"29400000","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719167400,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API)(PHARMACEUTICALS RAW MATERIAL) PRODUCTNAME- ACALABRUTINIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"TO THE ORDER OF","customerCountry":"RUSSIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"36000","totalValueFC":"7110.2","currency":"USD","unitRateINR":2967784.9499999997,"date":"24-Jun-2024","totalValueINR":"593556.99","totalValueInUsd":"7110.2","indian_port":"Ahmedabad Air","hs_no":"29334900","bill_no":"1909044","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734028200,"product":"ACALABRUTINIB(0.100 KGS)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"PARIS - CHARLES DE G","customer":"SANOFI AVENTIS RECHERCHE","customerCountry":"FRANCE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"83000","totalValueFC":"6418.2","currency":"USD","unitRateINR":5453500,"date":"13-Dec-2024","totalValueINR":"545350","totalValueInUsd":"6418.2","indian_port":"Hyderabad Air","hs_no":"29400000","bill_no":"6423527","productDescription":"API","marketType":"REGULATED MARKET","country":"FRANCE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729794600,"product":"ACALABRUTINIB","address":"101, SITARAM MANSION,","city":"KAROL BAGH, NEW DELHI","supplier":"SICHUAN TAIENKANG PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"CHENGDU","customer":"JODAS EXPOIM PVT. LTD","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"8800","totalValueFC":"8896.7","currency":"USD","unitRateINR":"747560","date":"25-Oct-2024","totalValueINR":"747560","totalValueInUsd":"8896.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6321991","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"CHENGDU","supplierAddress":"NO.22 JIANKANG ROAD ECONOMIC DEVELO PMENT ZONE YUECHI COUNTY 638300 SDNF China","customerAddress":"101, SITARAM MANSION,"}]
20-Mar-2021
13-Dec-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Europe

read-more
read-more

01

AstraZeneca AG

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

Brand Name : Calquence

Dosage Form : Caps

Dosage Strength : 100mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

02

AstraZeneca AG

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Acalabrutinib

Brand Name : Calquence

Dosage Form : Film-Coated Tablets

Dosage Strength : 100mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Coating Systems & Additives

read-more
read-more

Empty Capsules

read-more
read-more

Granulation

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Coloring Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1420477-60-6 / Acalabrutinib API manufacturers, exporters & distributors?

Acalabrutinib manufacturers, exporters & distributors 1

16

PharmaCompass offers a list of Acalabrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Acalabrutinib manufacturer or Acalabrutinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acalabrutinib manufacturer or Acalabrutinib supplier.

PharmaCompass also assists you with knowing the Acalabrutinib API Price utilized in the formulation of products. Acalabrutinib API Price is not always fixed or binding as the Acalabrutinib Price is obtained through a variety of data sources. The Acalabrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Acalabrutinib

Synonyms

1420477-60-6, Acp-196, Calquence, Acalabrutinib (acp-196), Acalabrutinib [inn], I42748elqw

Cas Number

1420477-60-6

Unique Ingredient Identifier (UNII)

I42748ELQW

About Acalabrutinib

Acalabrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Calquence Manufacturers

A Calquence manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calquence, including repackagers and relabelers. The FDA regulates Calquence manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calquence API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Calquence manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Calquence Suppliers

A Calquence supplier is an individual or a company that provides Calquence active pharmaceutical ingredient (API) or Calquence finished formulations upon request. The Calquence suppliers may include Calquence API manufacturers, exporters, distributors and traders.

click here to find a list of Calquence suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Calquence USDMF

A Calquence DMF (Drug Master File) is a document detailing the whole manufacturing process of Calquence active pharmaceutical ingredient (API) in detail. Different forms of Calquence DMFs exist exist since differing nations have different regulations, such as Calquence USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Calquence DMF submitted to regulatory agencies in the US is known as a USDMF. Calquence USDMF includes data on Calquence's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calquence USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Calquence suppliers with USDMF on PharmaCompass.

Calquence KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Calquence Drug Master File in Korea (Calquence KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Calquence. The MFDS reviews the Calquence KDMF as part of the drug registration process and uses the information provided in the Calquence KDMF to evaluate the safety and efficacy of the drug.

After submitting a Calquence KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Calquence API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Calquence suppliers with KDMF on PharmaCompass.

Calquence WC

A Calquence written confirmation (Calquence WC) is an official document issued by a regulatory agency to a Calquence manufacturer, verifying that the manufacturing facility of a Calquence active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Calquence APIs or Calquence finished pharmaceutical products to another nation, regulatory agencies frequently require a Calquence WC (written confirmation) as part of the regulatory process.

click here to find a list of Calquence suppliers with Written Confirmation (WC) on PharmaCompass.

Calquence NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calquence as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Calquence API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Calquence as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Calquence and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calquence NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Calquence suppliers with NDC on PharmaCompass.

Calquence GMP

Calquence Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Calquence GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calquence GMP manufacturer or Calquence GMP API supplier for your needs.

Calquence CoA

A Calquence CoA (Certificate of Analysis) is a formal document that attests to Calquence's compliance with Calquence specifications and serves as a tool for batch-level quality control.

Calquence CoA mostly includes findings from lab analyses of a specific batch. For each Calquence CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Calquence may be tested according to a variety of international standards, such as European Pharmacopoeia (Calquence EP), Calquence JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calquence USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty